This site is not intended to provide medical advice and/or treatment guidance. It is produced by Roche as a partner of Foundation Medicine.
Please select an option:
!
We use cookies to help provide you with a better service. You can change your cookie settings at any time. Otherwise, we will assume you're OK to continue.
A portfolio of extensively validated comprehensive profiling services to guide treatment and research decisions at optimal times beneficial to your patients’ journeys
Foundation Medicine’s portfolio of extensively validated comprehensive genomic profiling services provides powerful insights to guide efficient, personalised treatment decisions at optimal times beneficial to your patients’ journeys:1–8
All of Foundation Medicine’s services use our leading comprehensive genomic profiling approach, which broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients’ treatment options.1,2,4,5,7–13
As our understanding of cancer evolves, so do our tests
Our continuously growing genomic database currently includes over 400,000 genomic profiles in over 150 common and rare tumour subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights.14 Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.1,2,4,5
References
Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.